Literature DB >> 12952291

Immunotoxin therapy for CNS tumor.

Edward Rustamzadeh1, Walter C Low, Daniel A Vallera, Walter A Hall.   

Abstract

Surgery, chemotherapy, and radiation therapy have become standard of practice in treating malignant brain tumors. Unfortunately, the prognosis of these malignant tumors still remains poor. Immunotoxins are a relatively new adjuvant treatment for brain tumors. Within the last few years an increased amount of clinically-oriented research involving immunotoxins has been published. This has led to numerous clinical trials which although encouraging have not yet born out the "magic bullet" concept envisioned for immunotoxins. In this review article the history, design, toxicity, and pharmokinetics of immunotoxins will be discussed in detail.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12952291     DOI： 10.1007/BF02700025

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  167 in total

1.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies.

Authors:  J R Glenney; W S Chen; C S Lazar; G M Walton; L M Zokas; M G Rosenfeld; G N Gill
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

3.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

Review 4.  Interleukin-4 and cancer therapy.

Authors:  R K Puri; J P Siegel
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

5.  Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

Authors:  P Riva; G Franceschi; A Arista; M Frattarelli; N Riva; A M Cremonini; G Giuliani; M Casi
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

6.  Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma.

Authors:  H Liu; B S Jacobs; J Liu; R A Prayson; M L Estes; G H Barnett; B P Barna
Journal:  Cancer Immunol Immunother       Date:  2000-08       Impact factor: 6.968

7.  Epidermal growth factor binding in intracranial neoplasms: preliminary biochemical and clinicopathological findings.

Authors:  I R Whittle; R A Hawkins; E Killen; J D Miller
Journal:  Br J Neurosurg       Date:  1988       Impact factor: 1.596

8.  The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors.

Authors:  M J Rutigliano; L D Lunsford; D Kondziolka; M J Strauss; V Khanna; M Green
Journal:  Neurosurgery       Date:  1995-09       Impact factor: 4.654

9.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

10.  Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells.

Authors:  R K Schmidt-Ullrich; K Valerie; P B Fogleman; J Walters
Journal:  Radiat Res       Date:  1996-01       Impact factor: 2.841
View more
  10 in total

1.  Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.

Authors:  Neal Luther; Nai-Kong Cheung; Eleni P Souliopoulos; Ioannis Karampelas; Ioannis Karempelas; Daniel Bassiri; Mark A Edgar; Hong-Fen Guo; Ira Pastan; Philip H Gutin; Mark M Souweidane
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

2.  The conjugation of an AQP1-directed immunotoxin in the study of site-directed therapy within the CNS.

Authors:  Surash Surash; Peter Nemeth; Aruna Chakrabarty; Paul Chumas
Journal:  Childs Nerv Syst       Date:  2010-11-23       Impact factor: 1.475

3.  Clinical development of experimental therapies for malignant glioma.

Authors:  Nikolai G Rainov; Volkmar Heidecke
Journal:  Sultan Qaboos Univ Med J       Date:  2011-02-12

4.  Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.

Authors:  Edward Rustamzadeh; Daniel A Vallera; Deborah A Todhunter; Walter C Low; Angela Panoskaltsis-Mortari; Walter A Hall
Journal:  J Neurooncol       Date:  2006-05       Impact factor: 4.130

Review 5.  Diphtheria toxin-based targeted toxin therapy for brain tumors.

Authors:  Yan Michael Li; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2013-05-22       Impact factor: 4.130

Review 6.  Brain tumor immunotherapy: an immunologist's perspective.

Authors:  Lois A Lampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

7.  Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

Authors:  Rushika M Perera; Roberto Zoncu; Terrance G Johns; Marc Pypaert; Fook-Thean Lee; Ira Mellman; Lloyd J Old; Derek K Toomre; Andrew M Scott
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

Review 8.  Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.

Authors:  Lee A Selznick; Mohammed F Shamji; Peter Fecci; Matthias Gromeier; Allan H Friedman; John Sampson
Journal:  Neurosurg Rev       Date:  2008-02-08       Impact factor: 3.042

9.  Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.

Authors:  Jun Huang; Yan Michael Li; Joan Massague; Andy Sicheneder; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2012-06-14       Impact factor: 4.506

Review 10.  Targeted toxins in brain tumor therapy.

Authors:  Yan Michael Li; Walter A Hall
Journal:  Toxins (Basel)       Date:  2010-11-01       Impact factor: 5.075
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.